CLDX

Celldex Therapeutics Inc

Add to Watchlist

Advanced Chart

22.360

+0.3(1.360%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

22.670

Open

21.800

VWAP

22.32

Vol

717.51K

Mkt Cap

1.48B

Low

21.710

Amount

16.02M

EV/EBITDA(TTM)

Total Shares

65.91M

814.60M

EV/OCF(TTM)

P/S(TTM)

196.46

Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

1.26M

+7.3%

1.18M

-62.9%

1.13M

-54.67%

Estimates Revision

The market is revising Downward the revenue expectations for Celldex Therapeutics, Inc. (CLDX) for FY2025, with the revenue forecasts being adjusted by -17.77% over the past three months. During the same period, the stock price has changed by 15.08%.

Revenue Estimates for FY2025

Revise Downward

-17.77%

In Past 3 Month

Stock Price

Go Up

+15.08%

In Past 3 Month

9 Analyst Rating

142.80% Upside

Wall Street analysts forecast CLDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLDX is 54.29 USD with a low forecast of 38.00 USD and a high forecast of 74.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

0 Hold

0 Sell

Strong Buy

142.80% Upside

Current: 22.360

Low

38.00

Averages

54.29

High

74.00

142.80% Upside

Current: 22.360

Low

38.00

Averages

54.29

High

74.00

RBC Capital

Outperform -> Sector Perform

downgrade

$46 -> $5

2025-07-08

Reason

RBC Capital

Price Target

$46 -> $5

2025-07-08

downgrade

Outperform -> Sector Perform

Reason

As previously reported, RBC Capital downgraded Jasper Therapeutics (JSPR) to Sector Perform from Outperform with a price target of $5, down from $46. While the firm thinks Jasper's early data supports a rapid onset of complete response that may remain durable and a better safety profile, positioning lead asset briquilimab favorably against key competitor Celldex's (CLDX) agent barzolvolimab, it argues that questions around manufacturing, cash runway, relative timing versus Celldex and the degree of differentiation will be "challenging to fully address in the near-term" following yesterday's updates. The firm is stepping to the sidelines pending greater visibility on a path forward for briquilimab, the analyst tells investors.

H.C. Wainwright

Joseph Pantginis

Buy

downgrade

$80 -> $50

2025-05-09

Reason

H.C. Wainwright

Joseph Pantginis

Price Target

$80 -> $50

2025-05-09

downgrade

Buy

Reason

H.C. Wainwright analyst Joseph Pantginis lowered the firm's price target on Celldex to $50 from $80 and keeps a Buy rating on the shares following the Q1 report. The firm expects 2025 to be a year of continued execution across the company's pipeline, and highlight the current status of the ongoing programs.

UBS

Buy

downgrade

$44 -> $38

2025-05-09

Reason

UBS

Price Target

$44 -> $38

2025-05-09

downgrade

Buy

Reason

UBS lowered the firm's price target on Celldex to $38 from $44 and keeps a Buy rating on the shares.

Morgan Stanley

Judah Frommer

Buy

Initiates

$46

2025-03-20

Reason

Morgan Stanley

Judah Frommer

Price Target

$46

2025-03-20

Initiates

Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$80

2025-03-03

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$80

2025-03-03

Reiterates

Strong Buy

Reason

Goldman Sachs

Richard Law

Hold

Maintains

$42 → $36

2025-03-03

Reason

Goldman Sachs

Richard Law

Price Target

$42 → $36

2025-03-03

Maintains

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Celldex Therapeutics Inc (CLDX.O) is -5.92, compared to its 5-year average forward P/E of -13.65. For a more detailed relative valuation and DCF analysis to assess Celldex Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-13.65

Current PE

-5.92

Overvalued PE

-7.73

Undervalued PE

-19.56

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.05

Current EV/EBITDA

-3.18

Overvalued EV/EBITDA

1.63

Undervalued EV/EBITDA

-5.72

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

552.24

Current PS

364.95

Overvalued PS

844.89

Undervalued PS

259.60

Financials

Annual

Quarterly

FY2025Q1

YoY :

+345.51%

695.00K

Total Revenue

FY2025Q1

YoY :

+54.50%

-62.74M

Operating Profit

FY2025Q1

YoY :

+63.97%

-53.80M

Net Income after Tax

FY2025Q1

YoY :

+44.64%

-0.81

EPS - Diluted

FY2025Q1

YoY :

+33.32%

-54.64M

Free Cash Flow

FY2025Q1

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2025Q1

YoY :

+15.14%

-2.29K

FCF Margin - %

FY2025Q1

YoY :

-63.19%

-7.74K

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

308.4K

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

131.9K

Volume

6-9

Months

41.4K

Volume

0-12

Months

0.0

Volume

Bought

0-3

150.0K

Volume

Months

3-6

2.1M

Volume

Months

6-9

3.8M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

308.4K

USD

Months

0-12

0.0

USD

Months

CLDX News & Events

Events Timeline

2025-06-15 (ET)

2025-06-15

20:23:51

Celldex announces data on barzolvolimab from its Phase 2 trial in CSU

2025-06-12 (ET)

2025-06-12

18:02:14

Celldex says Phase 2 Barzolvolimab study met primary endpoint

2025-06-06 (ET)

2025-06-06

08:05:39

Celldex appoints Torres to board of directors

News

8.0

07-17NASDAQ.COM

Interesting CLDX Put And Call Options For September 19th

9.0

06-14NASDAQ.COM

Celldex Therapeutics Reports 77% Angioedema-Free Rate at Week 52 in Phase 2 Trial of Barzolvolimab for Chronic Spontaneous Urticaria

9.0

06-14Newsfilter

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025